secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-10-09T23:59:59+00:00
Accession:  0000950170-24-113764
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo updates LX2020 cohort data timeline to late Q1/early Q2 2025; LX1001 data at CTAD Oct 2024
--------------------------------------------------------------------------------

- Expects to share Cohort 1 data from LX2020 for PKP2-ACM in late Q1 or early Q2 2025.
- Plans to present LX1001 data for APOE4-associated Alzheimer's at CTAD conference in Oct 2024.
- Corporate presentation posted on website; used for investor meetings going forward.
- No changes to financial guidance or capital structure disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024113764/0000950170-24-113764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024113764/lxeo-20241009.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer